全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Vitamin D Predicts All-Cause and Cardiac Mortality in Females with Suspected Acute Coronary Syndrome: A Comparison with Brain Natriuretic Peptide and High-Sensitivity C-Reactive Protein

DOI: 10.1155/2013/398034

Full-Text   Cite this paper   Add to My Lib

Abstract:

Vitamin D may not only reflect disease but may also serve as a prognostic indicator. Our aim was to assess the gender-specific utility of vitamin D measured as 25-hydroxy-vitamin D [25(OH)D] to predict all-cause and cardiac death in patients with suspected acute coronary syndrome (ACS) and to compare its prognostic utility to brain natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hsCRP). Blood samples were harvested on admission in 982 patients. Forty percent were women (65.9 ± 12.6 years). Mortality was evaluated in quartiles of 25(OH)D, BNP, and hsCRP, respectively, during a 5-year follow-up, applying univariate and multivariate analyses. One hundred and seventy-three patients died; 78 were women. In 92 patients (37 women), death was defined as cardiac. In women, the univariate hazard ratio (HR) for total death of 25(OH)D in Quartile (Q) 2 versus Q1, Q3 versus Q1, and Q4 versus Q1 was 0.55 (95% CI 0.33–0.93), 0.29 (95% CI 0.15–0.55), and 0.13 (95% CI 0.06–0.32), respectively. In females, it was an independent predictor of total and cardiac death, whereas BNP and hsCRP were less gender-specific. No gender differences in 25(OH)D were noted in a reference material. Accordingly, vitamin D independently predicts mortality in females with suspected ACS. 1. Introduction Cardiovascular disease (CVD) is the primary cause of mortality both in men and women worldwide [1]. Women have been underrepresented in clinical trials [2]. They very often present with atypical symptoms and are frequently undiagnosed. Furthermore, their risk factors are understudied. Due to women’s higher age of disease manifestation, they are also more likely to have other diseases and comorbidities, rendering the diagnosis more difficult and complex. This has also resulted in less research related to the predictive utility of the established biomarkers in this gender. Recently, numerous observational and epidemiological studies suggest that vitamin D deficiency may be related to CVD and mortality [3–9] and is associated with myocardial infarction (MI) [10, 11] and sudden cardiac death (SCD) [12]. As vitamin D deficiency in men and women is increasing, we believe that the general diet does not contain a sufficient amount of this vitamin and/or that people do not spend enough time outdoors to create a sufficient amount of this vitamin upon sun exposure. In a previous study with 2-year follow-up [13], we found low levels of 25-hydroxy-vitamin D [25(OH)D] in a chest-pain population from Northern Argentina. This was an unexpected finding, as we assumed that our study

References

[1]  S. Mendis, P. Puska, and B. Norrving, Eds., Global Atlas on Cardiovascular Disease Prevention and Control, World Health Organization, Geneva, Switzerland, 2011.
[2]  L. Worrall-Carter, C. Ski, E. Scruth, M. Campbell, and K. Page, “Systematic review of cardiovascular disease in women: assessing the risk,” Nursing and Health Sciences, vol. 13, no. 4, pp. 529–535, 2011.
[3]  A. Kilkkinen, P. Knekt, A. Aro et al., “Vitamin D status and the risk of cardiovascular disease death,” American Journal of Epidemiology, vol. 170, no. 8, pp. 1032–1039, 2009.
[4]  T. J. Wang, M. J. Pencina, S. L. Booth et al., “Vitamin D deficiency and risk of cardiovascular disease,” Circulation, vol. 117, no. 4, pp. 503–511, 2008.
[5]  H. Dobnig, S. Pilz, H. Scharnagl et al., “Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality,” Archives of Internal Medicine, vol. 168, pp. 1340–1349, 2008.
[6]  Q. Sun, L. Shi, E. B. Rimm et al., “Vitamin D intake and risk of cardiovascular disease in US men and women,” American Journal of Clinical Nutrition, vol. 94, no. 2, pp. 534–542, 2011.
[7]  M. S. Hutchinson, G. Grimnes, R. M. Joakimsen, Y. Figenschau, and R. Jorde, “Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Troms? study,” European Journal of Endocrinology, vol. 162, no. 5, pp. 935–942, 2010.
[8]  M. L. Melamed, E. D. Michos, W. Post, and B. Astor, “25-hydroxyvitamin D levels and the risk of mortality in the general population,” Archives of Internal Medicine, vol. 168, no. 15, pp. 1629–1637, 2008.
[9]  J. L. Anderson, H. T. May, B. D. Horne et al., “Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population,” American Journal of Cardiology, vol. 106, no. 7, pp. 963–968, 2010.
[10]  E. Giovannucci, Y. Liu, B. W. Hollis, and E. B. Rimm, “25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study,” Archives of Internal Medicine, vol. 168, no. 11, pp. 1174–1180, 2008.
[11]  J. H. Lee, R. Gadi, J. A. Spertus, F. Tang, and J. H. O'Keefe, “Prevalence of vitamin D deficiency in patients with acute myocardial infarction,” American Journal of Cardiology, vol. 107, no. 11, pp. 1636–1638, 2011.
[12]  S. Pilz, W. M?rz, B. Wellnitz et al., “Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 10, pp. 3927–3935, 2008.
[13]  P. A. Naesgaard, R. A. León de la Fuente, S. T. Nilsen, L. Woie, T. Aarsland, and C. Brede, “Serum 25(OH)D is a 2-year predictor of all-cause mortality, cardiac death and sudden cardiac death in chest pain patients from Northern Argentina,” PLoS ONE, vol. 9, Article ID e43228, 2012.
[14]  K. Maeda, T. Tsutamoto, A. Wada, T. Hisanaga, and M. Kinoshita, “Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction,” American Heart Journal, vol. 135, no. 5, pp. 825–832, 1998.
[15]  O. Nakagawa, Y. Ogawa, H. Itoh et al., “Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload,” Journal of Clinical Investigation, vol. 96, no. 3, pp. 1280–1287, 1995.
[16]  A. M. Richards, M. G. Nicholls, E. A. Espiner et al., “B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction,” Circulation, vol. 107, no. 22, pp. 2786–2792, 2003.
[17]  J. A. de Lemos, D. A. Morrow, J. H. Bentley et al., “The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes,” New England Journal of Medicine, vol. 345, no. 14, pp. 1014–1021, 2001.
[18]  D. A. Morrow, J. A. de Lemos, M. S. Sabatine et al., “Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18,” Journal of the American College of Cardiology, vol. 41, no. 8, pp. 1264–1272, 2003.
[19]  T. Omland, A. Persson, L. Ng et al., “N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes,” Circulation, vol. 106, no. 23, pp. 2913–2918, 2002.
[20]  R. León de la Fuente, P. A. Naesgaard, S. T. Nilsen et al., “B-type natriuretic peptide and high sensitive C-reactive protein predict 2-year all cause mortality in chest pain patients: a prospective observational study from Salta, Argentina,” BMC Cardiovascular Disorders, vol. 11, article 57, 2011.
[21]  R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.
[22]  G. Liuzzo, L. M. Biasucci, J. R. Gallimore et al., “The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina,” New England Journal of Medicine, vol. 331, no. 7, pp. 417–424, 1994.
[23]  B. C. Berk, W. S. Weintraub, and R. W. Alexander, “Elevation of C-reactive protein in “active” coronary artery disease,” American Journal of Cardiology, vol. 65, no. 3, pp. 168–172, 1990.
[24]  P. M. Ridker, “Clinical application of C-reactive protein for cardiovascular disease detection and prevention,” Circulation, vol. 107, no. 3, pp. 363–369, 2003.
[25]  M. Müller-Bardorff, K. Hallermayer, A. Schr?der et al., “Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation,” Clinical Chemistry, vol. 43, no. 3, pp. 458–466, 1997.
[26]  T. Killip III and J. T. Kimball, “Treatment of myocardial infarction in a coronary care unit. A Two year experience with 250 patients,” The American Journal of Cardiology, vol. 20, no. 4, pp. 457–464, 1967.
[27]  J.-A. Eastwood and L. V. Doering, “Gender differences in coronary artery disease,” The Journal of Cardiovascular Nursing, vol. 20, no. 5, pp. 340–353, 2005.
[28]  N. Bello and L. Mosca, “Epidemiology of coronary heart disease in women,” Progress in Cardiovascular Diseases, vol. 46, no. 4, pp. 287–295, 2004.
[29]  M. F. Holick and M. Garabedian, “Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications,” in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, M. J. Favus, Ed., pp. 106–114, 2006.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413